Hemab Therapeutics Holdings, Inc.
COAG
$54.94
$0.991.84%
NASDAQ
| 06/30/2026 | 03/31/2026 | 06/30/2025 | |||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | ||
| Total Other Revenue | -- | -- | -- | ||
| Total Revenue | -- | -- | -- | ||
| Cost of Revenue | -- | -- | -- | ||
| Gross Profit | -- | -- | -- | ||
| SG&A Expenses | 5.74M | 4.15M | 3.18M | ||
| Depreciation & Amortization | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | ||
| Total Operating Expenses | 26.08M | 23.61M | 16.06M | ||
| Operating Income | -26.08M | -23.61M | -16.06M | ||
| Income Before Tax | -24.05M | -22.68M | -12.21M | ||
| Income Tax Expenses | 97.00K | 12.00K | 4.00K | ||
| Earnings from Continuing Operations | -24.15M | -22.69M | -12.21M | ||
| Earnings from Discontinued Operations | -- | -- | -- | ||
| Extraordinary Item & Accounting Change | -- | -- | -- | ||
| Minority Interest in Earnings | -- | -- | -- | ||
| Net Income | -24.15M | -22.69M | -12.21M | ||
| EBIT | -26.08M | -23.61M | -16.06M | ||
| EBITDA | -26.00M | -23.54M | -15.98M | ||
| EPS Basic | -0.80 | -23.98 | -12.91 | ||
| Normalized Basic EPS | -0.50 | -14.98 | -8.92 | ||
| EPS Diluted | -0.80 | -23.98 | -12.91 | ||
| Normalized Diluted EPS | -0.50 | -14.98 | -8.92 | ||
| Average Basic Shares Outstanding | 30.11M | 946.00K | 946.00K | ||
| Average Diluted Shares Outstanding | 30.11M | 946.00K | 946.00K | ||
| Dividend Per Share | -- | -- | -- | ||
| Payout Ratio | -- | -- | -- | ||